Recaticimab

Recaticimab (SHR-1209) is an orally active humanized monoclonal IgG1 antibody targeting PCSK9. Recaticimab binds PCSK9 with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia[1][2].

Product Specifications

CAS Number

[2361290-85-7]

Product Name Alternative

SHR-1209

UNSPSC

12352203

Target

LDLR; PCSK9

Type

Inhibitory Antibodies

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/recaticimab.html

Purity

99.71

Solubility

10 mM in DMSO

Smiles

[Recaticimab]

Molecular Weight

(148.42 kDa)

References & Citations

[1]Xu M, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study. BMC Med. 2022 Jan 18;20 (1) :13. |[2]Gupta K, et al. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023 Dec;25 (12) :965-978.